| Literature DB >> 29092052 |
Laurent Dortet1,2,3,4, Philippe Glaser4,5, Najiby Kassis-Chikhani6, Delphine Girlich2,3,4, Philippe Ichai7, Marc Boudon7, Didier Samuel7, Elodie Creton2,3,4, Dilek Imanci8, Rémy Bonnin2,3,4, Nicolas Fortineau1,2,3,4, Thierry Naas1,2,3,4.
Abstract
OBJECTIVES: Patient- and procedure-related changes in modern medicine have turned CoNS into one of the major nosocomial pathogens. Treatments of CoNS infections are challenging owing to the large proportion of MDR strains and oxazolidinones often remain the last active antimicrobial molecules. Here, we have investigated a long-lasting outbreak (2010-13) due to methicillin- and linezolid-resistant (LR) CoNS (n = 168), involving 72 carriers and 49 infected patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29092052 PMCID: PMC5890688 DOI: 10.1093/jac/dkx370
Source DB: PubMed Journal: J Antimicrob Chemother ISSN: 0305-7453 Impact factor: 5.790
Figure 1.Timeline of the outbreak caused by LR-CoNS and correlation with global linezolid consumption. (a) Time flow chart of LR-CoNS isolates recovered from September 2010 to December 2013. Each square corresponds to one isolate. Species identification and the presence of the cfr gene are indicated according to the legend under the chart. (b) Comparison of the number of LRSE isolates recovered from 2011 to 2014 in hospitals B and PB, two tertiary care university teaching hospitals located 2 km apart, and correlation with the defined daily doses (DDDs) of linezolid per 1000 days of hospitalization (HD). (c) Numbers of patients colonized and/or infected with LRSE per month in the ICU of hospital PB and correlation with linezolid consumption in this unit in 2014. LZD, linezolid.
Susceptibility of LR-CoNS (n = 168) to last-resort antimicrobial families (glycopeptides, daptomycin, fifth-generation cephalosporins and oxazolidinones)
| Antimicrobial class | Agent | MIC range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | EUCAST MIC breakpoint (mg/L) |
|---|---|---|---|---|---|
| Glycopeptides | vancomycin | 0.75–4 | 1.5 | 2 | 4 |
| teicoplanin | 0.5–6 | 2.5 | 4 | 4 | |
| Lipopeptide | daptomycin | 0.12–1 | 0.25 | 0.5 | 1 |
| β-Lactams | ceftobiprole | 0.12–1 | 0.75 | 1 | 2 |
| ceftaroline | 0.06–0.5 | 0.25 | 0.5 | 1 | |
| Oxazolidinones | linezolid | 6 to >256 | 128 | 256 | 4 |
| tedizolid | 2 to >32 | 8 | 32 | 0.5 |
Figure 2.Genetic relatedness and cfr expression of LRSE isolates. Maximum likelihood phylogenetic tree based on sequence variation in the core genome from the 47 LRSE isolates submitted to WGS with 9 strains belonging to different STs. Respective STs deduced from WGS data are indicated (ST2, ST5 and ST22). Presence of cfr is indicated by a + sign for cfr+ LRSE isolates.
Figure 3.Maximum likelihood phylogenetic tree based on sequence variation in the core genome. (a) ST2 LRSE isolates. (b) ST5 LRSE isolates. (c) ST22 LRSE isolates. The orange Δ indicates a deletion of 13946 bp in genes located in the SCCmec cassette region (Figure S2). The green ‘SCC’ indicates the presence of an additional SCC cassette. Patient and isolate numbers are indicated on the left of the tree. Colonization or infection is indicated in the first column (C in red box for colonization, I in green box for infection). Acquired resistance genes for β-lactams, aminoglycosides, fusidic acid, fosfomycin, linezolid, phenicols and macrolides are indicated as follows: + in a dark or coloured box, presence; - in a white box, absence. Mutations in chromosome-encoded genes involved in quinolone and linezolid resistance are represented. WT, WT gene; MUT, presence of a mutation known to be responsible for phenotypic resistance; 2576, G2576U point mutation in the V domain of the 23S rRNA gene (rrl); 2534, C2534U point mutation in the V domain of the 23S rRNA gene; 2504, U2504A point mutation in the V domain of the 23S rRNA gene. Plasmid-acquired genes boxed with the same colour (purple, blue, brown and red) are located on the same plasmid [blue, p-cfr-PBR-A plasmid of 38745 bp (Figure 4a); red, p-cfr-PBR-B plasmid of 40182 bp (Figure 4b)].
Figure 4.Comparison of the two cfr-harbouring plasmids with related plasmids. (a) p-cfr-PBR-A: (1) corresponds to the cfr-carrying plasmid recovered from S. cohnii (GenBank NG_041657); (2) corresponds to the cfr-carrying plasmid recovered from ST2 LRSE isolates, p-cfr-PBR-A; (3) corresponds to the cfr-carrying plasmid recovered from S. aureus (GenBank KC206006). (b) p-cfr-PBR-B: (1) pSP01 cfr-encoding plasmid recovered from an S. epidermidis strain isolated in Italy; (2) corresponds to the cfr-carrying plasmid recovered from ST5 LRSE isolates, p-cfr-PBR-B. Common features are highlighted with beige shading. Gene names are as follows: res, resolvase; priC, primase C; ssa-like, secretory antigen Ssa-like; radC, DNA repair protein RadC; repA, replicase; tnp, transposase; cfr, chloramphenicol/florfenicol resistance; fexA, florfenicol/chloramphenicol efflux pump. Genes encoding antimicrobial resistance determinants are represented in red. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
MICs for ST2 and ST5 Cfr-producing S. epidermidis isolates, S. capitis DAM and S. capitis DAM transconjugants
| Antimicrobial agent | MIC (mg/L) | ||||
|---|---|---|---|---|---|
| >256 | >256 | 12 | 12 | 1 | |
| Tedizolid | 32 | 3 | 0.25 | 0.25 | 0.25 |
| Ceftobiprole | 1 | 0.75 | 0.064 | 0.064 | 0.064 |
| Ceftaroline | 0.25 | 0.19 | 0.032 | 0.032 | 0.032 |
| Vancomycin | 3 | 1 | 1 | 1 | 1 |
| Teicoplanin | 2 | 0.75 | 0.25 | 0.25 | 0.25 |
| Daptomycin | 0.38 | 0.19 | 0.75 | 0.75 | 0.75 |
| Fosfomycin | 24 | 1 | >1024 | >1024 | >1024 |
| >256 | >256 | >256 | >256 | 0.047 | |
| 256 | 64 | 256 | 64 | 4 | |
| Erythromycin | 64 | 8 | 0.25 | 0.25 | 0.25 |
Antimicrobial agents for which susceptibility is impacted by Cfr-dependent 23S RNA methylation are in bold.
The two plasmids indicated in brackets were transferred into S. capitis DAM strain by conjugation.
Characteristics of patients (n = 23) with cfr-positive linezolid- and methicillin-resistant S. epidermidis (cfr-positive LRSE)
| Male, | 15 (65) |
| Age (years), mean (SD) | 59.1 (9) |
| SAPS 2 score, mean (SD) | 44.7 (15) |
| Diagnostic group, | |
| medical | 15 (65) |
| surgical | 8 (35) |
| Cancer, | 5 (22) |
| Hospitalized in ICU prior to isolation of LRSE, | 19 (83) |
| SOFA score, mean (SD) | 9.0 (4) |
| vasopressors, | 12 (52) |
| Prior antibiotic | |
| broad-spectrum >5 days, | 17 (74) |
| fluoroquinolones, | 3 (13) |
| linezolid | |
| length of use (days), median (IQR) | 18 (13–27) |
| total dose (mg), median, (IQR) | 10800 (7500–15900) |
| Total length of stay (days), mean (SD) | |
| hospital | 109.9 (69) |
| ICU | 36.8 (35) |
| Mortality, | 10 (43) |
| ICU | 7 (30) |
| another unit | 3 (13) |
| Infection with LRSE, | 14 (61) |
| Colonization with LRSE, | 9 (39) |
Figure 5.Synoptic curve of patients infected or colonized with cfr-positive LRSE. The number in front of each line corresponds to the patient number. A patient number in bold signifies that the patient has been considered infected with a cfr-positive LRSE. A number not in bold indicates that the cfr-positive LRSE has been considered as a colonizer. The periods corresponding to the three successive outbreaks are indicated below the x-axis. The colour code corresponds to related strain (ST and cfr-encoding plasmid). Colour codes for hospitalization unit are indicated under the chart.